Tyche Industries Ltd (TYCHE)

Loading page…

Tyche Industries Ltd (TYCHE) · mywealthgrid

About

Tyche Industries Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹107 Cr

P/E

5.4×

P/B

0.8×

Dividend yield

3.3%

ROE

ROCE

6.8%

Debt / equity

OPM

4.2%

EPS (TTM)

₹19.5

Book value

₹137.1

52-week high

—

52-week low

—

2,173 historical price candles were omitted because the exchange source has not been verified.

₹105.0+0.5%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)
+Dividend yield of 3.3%
+High promoter holding of 62% with no pledge

Cons

−Low return on equity of 8.2% (3-yr avg)
−Thin operating margin of 4.2%
−Profit declined 19.1% a year over the last 5 years
−Revenue shrank over the last 5 years (-7.3% a year)

Research score

Structured signal from quality, growth, valuation and momentum.

46/100

Business quality: 26
Growth: 11

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	48	42	52	54	71	78	62	75	70	65	54
COGS	-29	-19	-23	-24	-29	27	28	34	29	25	24
Gross profit	—	—	—	—	—	51	35	42	40	41	29
	80	56	66	69	81	27	24	26	28	29	27
	-3	6	9	9	18	25	11	16	13	11	2
OPM %	-7.2%	13.3%	16.7%	17%	26.1%	31.6%	17.6%	21.4%	18.2%	17.2%	4.2%
Depreciation	2	2	—	2	2	2	2	2	2	2	2
Interest	0	0	0	—	—	0	0	0	0	0	0
	2	2	2	3	7	4	3	5	6	7	9
Profit before tax	3	6	9	10	23	27	13	19	17	17	9
Tax	0	3	3	3	6	7	3	5	4	4	3
Tax %	3.5%	47.9%	33.8%	27.3%	24.7%	25.3%	26.2%	25.7%	26.4%	25.8%	26.7%
	2	3	6	7	18	20	9	14	12	12	7
PAT margin %	5.2%	7.3%	11.4%	13.3%	24.8%	25.5%	15%	18.8%	17.6%	19%	12.9%
EPS (₹)	2.4	3	5.5	7	17.1	19.3	—	—	—	—	6.7
EPS adjusted (₹)	—	—	—	—	—	19.5	9.1	13.8	11.9	12.1	6.8
	20.7%	16.6%	9.1%	7.2%	5.8%	5.2%	—	—	—	—	52.2%
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	10	10	10	10	10	10
Reserves	86	94	107	116	126	130
	0	0	0	0	0	0
	21	16	20	8	11	8
Total equity & liabilities	117	120	137	135	147	148
	18	17	17	18	16	19
CWIP	1	0	—	0	0	0
Investments	0	0	0	0	0	0
	98	104	120	117	131	129
Total assets	117	120	137	135	147	148

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	15	4	6	8	9	3
	0	3	-3	4	-1	-9
	-1	-1	-2	-2	-3	-3
Net cash flow	15	7	2	10	5	-9
Free cash flow	13	4	5	4	8	-1
CFO / Operating profit %	62.5%	40.9%	39.8%	61%	75.6%	127.2%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	65.7%	55.5%	55.4%	58%	62.1%	55%
EBITDA margin %	17%	26.1%	31.6%	17.6%	21.4%	18.2%	17.2%	4.2%
EBIT margin %	13.6%	23.6%	29.4%	14.7%	19.1%	15.4%	14.2%	0.4%
PAT margin %	13.3%	24.8%	25.5%	15%	18.8%	17.6%	19%	12.9%
Working capital
Receivable days	—	—	80	96	107	100	95	133
Inventory days	—	—	149	148	195	157	245	150
Payable days	—	—	93	78	134	48	85	38
NWC days	—	—	135	167	168	210	255	245
Leverage
Current ratio	—	—	5.41	7.87	6.79	16.9	12.57	16.46
Debt to EBITDA	—	—	0	0	0	0	0	0
Debt to equity	—	—	0	0	0	0	0	0
Interest coverage	—	—	2,773	—	—	—	—	—
Asset turnover	—	—	0.67	0.52	0.55	0.52	0.44	0.36
Return ratios
Return on assets %	—	—	17.1%	7.8%	10.4%	9.1%	8.4%	4.7%
Return on capital employed %	—	—	28%	12.9%	16.9%	13.4%	12.6%	6.8%
Return on equity %	—	—	20.8%	9%	12.1%	9.7%	9.1%	4.9%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	61.97%	61.97%	61.97%	61.97%	61.97%	61.97%	61.97%	61.97%	62.05%	61.97%	61.97%	61.97%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	38.03%	38.03%	38.03%	38.03%	38.03%	38.03%	38.03%	38.03%	37.95%	38.03%	38.03%	38.03%
No. of shareholders	—	—	—	—	—	—	—	—	7,257	7,152	6,952	6,786

Promoter holding up 0 percentage points since Sep 2023.

Mr. SANDEEP GOKARAJUExecutive Director-Chairperson-MD
Mr. G GANESH KUMARExecutive Director
Mr. SAI SUDHAKAR PANCHAKARLANon-Executive - Independent Director
Mrs. VIJAYA LAKSHMI PENUMATSANon-Executive - Independent Director
Mr. VENKATARAJU GUPTA KOLLEPALLINon-Executive - Independent Director
Mr. Y.Srinivasa RaoChief Financial Officer
Mr. SRINIVAS GELLINon-Executive - Independent Director
Mr. SATYA SRINIVAS UPPALAPATIExecutive Director
Mr. Pradosh Ranjan JenaCompany Secretary cum Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Tyche Industries Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

20

Final dividend23 Sept 2026 · ex-date₹3.5
Final dividend19 Sept 2025 · ex-date₹3
Final dividend20 Sept 2024 · ex-date₹2.5
Dividend dividend22 Aug 2023 · ex-date₹2
Final dividend22 Sept 2022 · ex-date₹1.5
Dividend dividend22 Sept 2021 · ex-date₹1
Dividend dividend22 Sept 2020 · ex-date₹1
Final dividend20 Sept 2019 · ex-date₹0.5
Final dividend19 Sept 2018 · ex-date₹0.5
Dividend dividend21 Sept 2017 · ex-date₹0.5
Dividend dividend22 Sept 2016 · ex-date₹0.5
Final dividend23 Sept 2015 · ex-date₹0.5
Final dividend25 Sept 2014 · ex-date₹0.5
Dividend dividend19 Sept 2013 · ex-date₹0.5
Dividend dividend24 Sept 2012 · ex-date₹0.5
Dividend dividend23 Sept 2011 · ex-date₹0.5
Dividend dividend22 Oct 2010 · ex-date₹0.5
Dividend dividend24 Sept 2009 · ex-date₹0.5
Dividend dividend24 Sept 2008 · ex-date₹0.5
Dividend dividend21 Sept 2007 · ex-date₹1.5

1

Board meeting to consider results11 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

15 announcementsExport CSV

1 Oct 2026, 6:32 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

30 Sept 2026, 3:39 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

5 Sept 2026, 11:24 amCompany Update

Corrigendum To The Annual Report For The Financial Year 2025-26

General PDF

3 Sept 2026, 12:18 pmCompany Update

Tyche Industries Ltd - 532384 - Intimation Under Regulations 30 And 36(1)(B) Of The SEBI Listing Regulations.

General PDF

3 Sept 2026, 10:58 amCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

3 Sept 2026, 10:57 amCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

2 Sept 2026, 3:28 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

2 Sept 2026, 2:55 pmCorp. Action

Intimation Of Record Date For The Purpose Of Payment Of Final Dividend For The F.Y. 2025-26.

Record Date PDF

Date	Category	Subject	Filing
1 Oct 2026, 6:32 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
30 Sept 2026, 3:39 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	65.7%	55.5%	55.4%	58%	62.1%	55%
EBITDA margin %	17%	26.1%	31.6%	17.6%	21.4%	18.2%	17.2%	4.2%
EBIT margin %	13.6%	23.6%	29.4%	14.7%	19.1%	15.4%	14.2%	0.4%
PAT margin %	13.3%	24.8%	25.5%	15%	18.8%	17.6%	19%	12.9%
Working capital
Receivable days	—	—	80	96	107	100	95	133
Inventory days	—	—	149	148	195	157	245	150
Payable days	—	—	93	78	134	48	85	38
NWC days	—	—	135	167	168	210	255	245
Leverage
Current ratio	—	—	5.41	7.87	6.79	16.9	12.57	16.46
Debt to EBITDA	—	—	0	0	0	0	0	0
Debt to equity	—	—	0	0	0	0	0	0
Interest coverage	—	—	2,773	—	—	—	—	—
Asset turnover	—	—	0.67	0.52	0.55	0.52	0.44	0.36
Return ratios
Return on assets %	—	—	17.1%	7.8%	10.4%	9.1%	8.4%	4.7%
Return on capital employed %	—	—	28%	12.9%	16.9%	13.4%	12.6%	6.8%
Return on equity %	—	—	20.8%	9%	12.1%	9.7%	9.1%	4.9%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Tyche Industries Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

20

1

Announcements

20

1

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Tyche Industries Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Dividends20

Board meetings1

Announcements

Dividends20

Board meetings1

Ratio timeline

Quarterly record

Board and management

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

20

1

20

1